Early reproductive failure is the most common issue related to successful pregnancies, as around 30% of all conceptions reach live birth. The path to a successful pregnancy is reliant on the successful implantation of the embryo to the endometrium. This event requires three major components; a viable embryo ready for implantation, a receptive endometrium in which the implantation will occur, and healthy crosstalk between the embryo and receptive endometrium. It is estimated that two out of all three implantation failures are related to endometrial origin. This has led many researchers to attempt to elucidate the mechanism behind endometrial receptivity and generate a prediction of successful implantation of endometrial origin. Although there have been plenty of articles on this subject, there is still no consensus regarding standard endometrial receptivity biomarkers. Additionally, most of these articles’ findings cannot find their way into clinics. This is highlighted by the fact that the success rate of embryo implantation in ART applied in clinics is only around 10%. This study aimed to identify novel methods and biomarkers to predict the endometrium's receptivity, which could be applied in clinics easier and faster than the current kits in the market. We took several different approaches to achieve this aim. The first was to identify and validate particular miRNAs that showed a change in expression levels of the different days of the endometrial cycle in a healthy women’s serum. Our bioinformatical analysis has yielded ten miRNAs that show statistical differences in the human endometrium and being expressed in the serum. Downstream RNA-Seq and qPCR experiments have validated specific miRNAs previously predicted and identified novel miRNAs used for this purpose. The second was using in silico methods, identifying novel genes present in the endometrium that can predict the optimal point of receptivity. If considered and validated in vitro, this novel gene-list will be a cheaper but still as powerful alternative to the current endometrial test kit used in clinics today. Further validation RNA-Seq experiments on healthy and infertile females will elucidate our novel biomarkers' strength, designed to be used in ART clinics worldwide. Furthermore, upon building on these findings, it is possible to uncover previously overlooked mechanisms leading to women's implantation success.